Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics

Detalhes bibliográficos
Autor(a) principal: Orofino-Costa, Rosane
Data de Publicação: 2017
Outros Autores: de Macedo, Priscila Marques, Rodrigues, Anderson Messias [UNIFESP], Bernardes-Engemann, Andrea Reis
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNIFESP
Texto Completo: http://dx.doi.org/10.1590/abd1806-4841.2017279
http://repositorio.unifesp.br/handle/11600/51239
Resumo: In the late 90' s there was a change in both the route of transmission and the people at risk for sporotrichosis. This zoonotic cat-man alternative transmission route elicited changes in strategies to control the epidemic. There was a progressive increase in the number of cases involving especially children and the elderly. In addition to becoming hyperendemic, uncommon clinical pictures like immunoreactive clinical presentations or severe systemic cases have emerged. New species were identified and classified through molecular tools using more virulent clinical isolates, like S. brasiliensis, compared to the environmental isolates. Likewise, different species of Sporothrix have been associated with different geographic regions. The serological and molecular techniques are used as an auxiliary tool for the diagnosis and/or for species identification, although the isolation and the identification of Sporothrix spp. in clinical specimen is still the gold standard. Currently sporotrichosis epidemics requires the knowledge of the epidemiological-molecular profile to control the disease and the specific treatment. Itraconazole, potassium iodide, terfinafine, and amphotericin B are the available drugs in Brazil to treat sporotrichosis. The drug of choice, its posology, and treatment duration vary according to the clinical presentation, the Sporothrix species, and host immune status. New treatment choices, including a vaccine, are being developed
id UFSP_2d31467043c99bdfaa2b3ce8d0717c3a
oai_identifier_str oai:repositorio.unifesp.br/:11600/51239
network_acronym_str UFSP
network_name_str Repositório Institucional da UNIFESP
repository_id_str 3465
spelling Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeuticsDiagnosisEpidemiologyMolecular biologySerologySporothrixTherapeuticsIn the late 90' s there was a change in both the route of transmission and the people at risk for sporotrichosis. This zoonotic cat-man alternative transmission route elicited changes in strategies to control the epidemic. There was a progressive increase in the number of cases involving especially children and the elderly. In addition to becoming hyperendemic, uncommon clinical pictures like immunoreactive clinical presentations or severe systemic cases have emerged. New species were identified and classified through molecular tools using more virulent clinical isolates, like S. brasiliensis, compared to the environmental isolates. Likewise, different species of Sporothrix have been associated with different geographic regions. The serological and molecular techniques are used as an auxiliary tool for the diagnosis and/or for species identification, although the isolation and the identification of Sporothrix spp. in clinical specimen is still the gold standard. Currently sporotrichosis epidemics requires the knowledge of the epidemiological-molecular profile to control the disease and the specific treatment. Itraconazole, potassium iodide, terfinafine, and amphotericin B are the available drugs in Brazil to treat sporotrichosis. The drug of choice, its posology, and treatment duration vary according to the clinical presentation, the Sporothrix species, and host immune status. New treatment choices, including a vaccine, are being developednevertheless, more clinical trials are required to confirm its efficacy.Univ Estado Rio De Janeiro, FCM, Dermatol Dept, Rio De Janeiro, RJ, BrazilFundação Oswaldo Cruz INI Fiocruz, Infect Dermatol Clin Res Lab, Inst Nacl Infectol Evandro Chagas, Rio De Janeiro, RJ, BrazilUniv Fed São Paulo UNIFESP, Dept Microbiol Immunol & Parasitol, Lab Emerging Fungal Pathogen, São Paulo, SP, BrazilHosp Univ Pedro Ernesto, Med Mycol Lab, Dermatol Dept, Rio De Janeiro, RJ, BrazilUniv Fed São Paulo UNIFESP, Dept Microbiol Immunol & Parasitol, Lab Emerging Fungal Pathogen, São Paulo, SP, BrazilWeb of ScienceSoc Brasileira Dermatologia2019-08-19T11:48:22Z2019-08-19T11:48:22Z2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersion606-618application/pdfhttp://dx.doi.org/10.1590/abd1806-4841.2017279Anais Brasileiros De Dermatologia. Rio De Janeiro Rj, v. 92, n. 5, p. 606-618, 2017.10.1590/abd1806-4841.2017279WOS000416001300001.pdf0365-0596S0365-05962017000500606http://repositorio.unifesp.br/handle/11600/51239WOS:000416001300001enginfo:eu-repo/semantics/openAccessOrofino-Costa, Rosanede Macedo, Priscila MarquesRodrigues, Anderson Messias [UNIFESP]Bernardes-Engemann, Andrea Reisreponame:Repositório Institucional da UNIFESPinstname:Universidade Federal de São Paulo (UNIFESP)instacron:UNIFESP2024-08-02T23:37:25Zoai:repositorio.unifesp.br/:11600/51239Repositório InstitucionalPUBhttp://www.repositorio.unifesp.br/oai/requestbiblioteca.csp@unifesp.bropendoar:34652024-08-02T23:37:25Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)false
dc.title.none.fl_str_mv Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics
title Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics
spellingShingle Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics
Orofino-Costa, Rosane
Diagnosis
Epidemiology
Molecular biology
Serology
Sporothrix
Therapeutics
title_short Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics
title_full Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics
title_fullStr Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics
title_full_unstemmed Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics
title_sort Sporotrichosis: an update on epidemiology, etiopathogenesis, laboratory and clinical therapeutics
author Orofino-Costa, Rosane
author_facet Orofino-Costa, Rosane
de Macedo, Priscila Marques
Rodrigues, Anderson Messias [UNIFESP]
Bernardes-Engemann, Andrea Reis
author_role author
author2 de Macedo, Priscila Marques
Rodrigues, Anderson Messias [UNIFESP]
Bernardes-Engemann, Andrea Reis
author2_role author
author
author
dc.contributor.author.fl_str_mv Orofino-Costa, Rosane
de Macedo, Priscila Marques
Rodrigues, Anderson Messias [UNIFESP]
Bernardes-Engemann, Andrea Reis
dc.subject.por.fl_str_mv Diagnosis
Epidemiology
Molecular biology
Serology
Sporothrix
Therapeutics
topic Diagnosis
Epidemiology
Molecular biology
Serology
Sporothrix
Therapeutics
description In the late 90' s there was a change in both the route of transmission and the people at risk for sporotrichosis. This zoonotic cat-man alternative transmission route elicited changes in strategies to control the epidemic. There was a progressive increase in the number of cases involving especially children and the elderly. In addition to becoming hyperendemic, uncommon clinical pictures like immunoreactive clinical presentations or severe systemic cases have emerged. New species were identified and classified through molecular tools using more virulent clinical isolates, like S. brasiliensis, compared to the environmental isolates. Likewise, different species of Sporothrix have been associated with different geographic regions. The serological and molecular techniques are used as an auxiliary tool for the diagnosis and/or for species identification, although the isolation and the identification of Sporothrix spp. in clinical specimen is still the gold standard. Currently sporotrichosis epidemics requires the knowledge of the epidemiological-molecular profile to control the disease and the specific treatment. Itraconazole, potassium iodide, terfinafine, and amphotericin B are the available drugs in Brazil to treat sporotrichosis. The drug of choice, its posology, and treatment duration vary according to the clinical presentation, the Sporothrix species, and host immune status. New treatment choices, including a vaccine, are being developed
publishDate 2017
dc.date.none.fl_str_mv 2017
2019-08-19T11:48:22Z
2019-08-19T11:48:22Z
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.1590/abd1806-4841.2017279
Anais Brasileiros De Dermatologia. Rio De Janeiro Rj, v. 92, n. 5, p. 606-618, 2017.
10.1590/abd1806-4841.2017279
WOS000416001300001.pdf
0365-0596
S0365-05962017000500606
http://repositorio.unifesp.br/handle/11600/51239
WOS:000416001300001
url http://dx.doi.org/10.1590/abd1806-4841.2017279
http://repositorio.unifesp.br/handle/11600/51239
identifier_str_mv Anais Brasileiros De Dermatologia. Rio De Janeiro Rj, v. 92, n. 5, p. 606-618, 2017.
10.1590/abd1806-4841.2017279
WOS000416001300001.pdf
0365-0596
S0365-05962017000500606
WOS:000416001300001
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 606-618
application/pdf
dc.publisher.none.fl_str_mv Soc Brasileira Dermatologia
publisher.none.fl_str_mv Soc Brasileira Dermatologia
dc.source.none.fl_str_mv reponame:Repositório Institucional da UNIFESP
instname:Universidade Federal de São Paulo (UNIFESP)
instacron:UNIFESP
instname_str Universidade Federal de São Paulo (UNIFESP)
instacron_str UNIFESP
institution UNIFESP
reponame_str Repositório Institucional da UNIFESP
collection Repositório Institucional da UNIFESP
repository.name.fl_str_mv Repositório Institucional da UNIFESP - Universidade Federal de São Paulo (UNIFESP)
repository.mail.fl_str_mv biblioteca.csp@unifesp.br
_version_ 1814268403375931392